People need to read the reporting and not come up with objective figures and false information.
Lumos' primary business is in the manufacturing and services end. Their direct product line is in addition to this.
FY 2023 they generated $10.53Million in revenue. $302,000 of which was direct product sale (Febridx and Viradx) in Europe, Canada etc. Net Profit for this year was -$8.97Million which is a substantial reduction in 2022 due to reduced marketing costs, employee costs and impaired assets.
FY 2022 they generated $11.63Million in revenue. $2.2Million of which was direct product sales (primarily Covidx).
FY 2024 Lumos has announced the Hologic deal with initial $10Million in up front payments, and a further $4.7Million in revenue subject to development milestones.
It needs to be supported that the company made $1.7Million in the US alone for Covidx. They now have two products in market which generated $150,000 in 2 weeks in December. If Covidx gives any indication of what the pipeline offers, then we could see similar numbers from Febridx/Virdax in the US plus the existing services revenue and additional from this Hologic deal.
Edit: Noting that the most recent quarterly, there was already $1Million+ in revenue already generated pre Hologic announcement.
There is a good chance this is net positive this financial year, if not by next.
Add to My Watchlist
What is My Watchlist?
